JP2008512394A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008512394A5 JP2008512394A5 JP2007530543A JP2007530543A JP2008512394A5 JP 2008512394 A5 JP2008512394 A5 JP 2008512394A5 JP 2007530543 A JP2007530543 A JP 2007530543A JP 2007530543 A JP2007530543 A JP 2007530543A JP 2008512394 A5 JP2008512394 A5 JP 2008512394A5
- Authority
- JP
- Japan
- Prior art keywords
- substance
- epha4
- antagonist
- receptor
- rnai
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000021727 EphA4 Receptor Human genes 0.000 claims 16
- 108010055179 EphA4 Receptor Proteins 0.000 claims 16
- 239000000126 substance Substances 0.000 claims 16
- 238000000034 method Methods 0.000 claims 13
- 108091030071 RNAI Proteins 0.000 claims 8
- 230000009368 gene silencing by RNA Effects 0.000 claims 8
- 206010018341 Gliosis Diseases 0.000 claims 7
- 239000005557 antagonist Substances 0.000 claims 7
- 239000003795 chemical substances by application Substances 0.000 claims 6
- 102000050554 Eph Family Receptors Human genes 0.000 claims 5
- 108091008815 Eph receptors Proteins 0.000 claims 5
- 229940122293 Ephrin antagonist Drugs 0.000 claims 4
- 206010061218 Inflammation Diseases 0.000 claims 4
- 230000000692 anti-sense effect Effects 0.000 claims 4
- 210000003169 central nervous system Anatomy 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 4
- 230000007387 gliosis Effects 0.000 claims 4
- 230000004054 inflammatory process Effects 0.000 claims 4
- 108020004999 messenger RNA Proteins 0.000 claims 4
- 230000003376 axonal effect Effects 0.000 claims 3
- 206010061431 Glial scar Diseases 0.000 claims 2
- 208000027418 Wounds and injury Diseases 0.000 claims 2
- 230000006378 damage Effects 0.000 claims 2
- 208000014674 injury Diseases 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 210000000653 nervous system Anatomy 0.000 claims 2
- 230000008929 regeneration Effects 0.000 claims 2
- 238000011069 regeneration method Methods 0.000 claims 2
- 208000001738 Nervous System Trauma Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002518 glial effect Effects 0.000 claims 1
- 230000009036 growth inhibition Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 208000028412 nervous system injury Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000002464 receptor antagonist Substances 0.000 claims 1
- 229940044551 receptor antagonist Drugs 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 230000037390 scarring Effects 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 210000000278 spinal cord Anatomy 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2004905148A AU2004905148A0 (en) | 2004-09-08 | A method of treatment and agents useful for same | |
| AU2004905148 | 2004-09-08 | ||
| US64796805P | 2005-01-27 | 2005-01-27 | |
| US60/647,968 | 2005-01-27 | ||
| PCT/AU2005/001363 WO2006026820A1 (en) | 2004-09-08 | 2005-09-08 | Treating gliosis, glial scarring, inflammation or inhibition of axonal growth in the nervous system by modulating eph receptor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012030227A Division JP2012136529A (ja) | 2004-09-08 | 2012-02-15 | Ｅｐｈ受容体を調節することによる神経系内のグリオーシス、グリア瘢痕、炎症、または軸索成長阻害の処置 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008512394A JP2008512394A (ja) | 2008-04-24 |
| JP2008512394A5 true JP2008512394A5 (cg-RX-API-DMAC7.html) | 2008-10-09 |
| JP5094395B2 JP5094395B2 (ja) | 2012-12-12 |
Family
ID=36036018
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007530543A Expired - Fee Related JP5094395B2 (ja) | 2004-09-08 | 2005-09-08 | Ｅｐｈ受容体を調節することによる神経系内のグリオーシス、グリア瘢痕、炎症、または軸索成長阻害の処置 |
| JP2012030227A Withdrawn JP2012136529A (ja) | 2004-09-08 | 2012-02-15 | Ｅｐｈ受容体を調節することによる神経系内のグリオーシス、グリア瘢痕、炎症、または軸索成長阻害の処置 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012030227A Withdrawn JP2012136529A (ja) | 2004-09-08 | 2012-02-15 | Ｅｐｈ受容体を調節することによる神経系内のグリオーシス、グリア瘢痕、炎症、または軸索成長阻害の処置 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20080254023A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1793854A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP5094395B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2579352A1 (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ553273A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2006026820A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPP674898A0 (en) | 1998-10-27 | 1998-11-19 | Walter And Eliza Hall Institute Of Medical Research, The | A method of treatment |
| NZ553273A (en) * | 2004-09-08 | 2009-11-27 | Univ Melbourne | Treating gliosis, glial scarring, inflammation or inhibition of a xonal growth in the nervous system with an antagonist of EphA4-mediated signalling |
| EP2043638A2 (en) * | 2006-07-13 | 2009-04-08 | Novartis AG | Use of trifluoromethyl substituted benzamides in the treatment of neurological disorders |
| US8530181B2 (en) | 2007-11-15 | 2013-09-10 | Eisai R&D Management Co., Ltd. | Method of screening for compounds which affect the cleavage of EphA7 byγ-secretase |
| DK2223999T3 (en) * | 2007-11-30 | 2017-12-18 | Eisai R&D Man Co Ltd | EPHA4 POLYPEPTIDE WITH UNKNOWN ACTIVITY AND USE THEREOF |
| EP2260864A1 (en) * | 2009-06-10 | 2010-12-15 | University of Melbourne | Therapeutic applications |
| EP2653552B1 (en) | 2010-12-17 | 2016-10-19 | Eisai R&D Management Co., Ltd. | SCREENING METHOD USING GELATINASE-MEDIATED EphA4 CLEAVAGE REACTION AS AN INDICATOR |
| EP2703814B1 (en) | 2011-04-25 | 2017-11-01 | Eisai R&D Management Co., Ltd. | Method for detecting neurological disease associated with cognitive dysfunction by measuring epha4 extracellular domain |
| EP3169344B1 (en) | 2014-07-15 | 2021-09-29 | Sanford Burnham Prebys Medical Discovery Institute | Epha4 cyclic peptide antagonists for neuroprotection and neural repair |
| RU2651756C1 (ru) * | 2017-05-10 | 2018-04-23 | Федеральное государственное бюджетное образовательное учреждение Высшего Образования Кубанский Государственный Медицинский Университет Министерства Здравоохранения Российской Федерации, КубГМУ | Препарат для предотвращения образования глиальных рубцов |
| BR112021025161A2 (pt) | 2019-07-01 | 2022-01-25 | Eisai R&D Man Co Ltd | Anticorpo anti-epha4 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPP674898A0 (en) * | 1998-10-27 | 1998-11-19 | Walter And Eliza Hall Institute Of Medical Research, The | A method of treatment |
| ES2242437T3 (es) * | 1998-11-20 | 2005-11-01 | Genentech, Inc. | Utilizaciones de agonistas y antagonistas del receptor eph para el tratamiento de trastornos vasculares. |
| US8461119B2 (en) * | 2002-09-24 | 2013-06-11 | The Burnham Institute | Agents that modulate Eph receptor activity |
| US20040147469A1 (en) * | 2002-11-01 | 2004-07-29 | Case Western Reserve University | Methods of inhibiting glial scar formation |
| WO2005056766A2 (en) * | 2003-12-04 | 2005-06-23 | Medimmune, Inc. | TARGETED DRUG DELIVERY USING EphA2 OR Eph4 BINDING MOIETIES |
| NZ553273A (en) * | 2004-09-08 | 2009-11-27 | Univ Melbourne | Treating gliosis, glial scarring, inflammation or inhibition of a xonal growth in the nervous system with an antagonist of EphA4-mediated signalling |
-
2005
- 2005-09-08 NZ NZ553273A patent/NZ553273A/en not_active IP Right Cessation
- 2005-09-08 US US11/662,355 patent/US20080254023A1/en not_active Abandoned
- 2005-09-08 WO PCT/AU2005/001363 patent/WO2006026820A1/en not_active Ceased
- 2005-09-08 JP JP2007530543A patent/JP5094395B2/ja not_active Expired - Fee Related
- 2005-09-08 CA CA002579352A patent/CA2579352A1/en not_active Abandoned
- 2005-09-08 EP EP05778955A patent/EP1793854A4/en not_active Withdrawn
-
2012
- 2012-02-15 JP JP2012030227A patent/JP2012136529A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Mecca et al. | Cerebroprotection by angiotensin‐(1–7) in endothelin‐1‐induced ischaemic stroke | |
| Finlin et al. | Mast cells promote seasonal white adipose beiging in humans | |
| Arborelius et al. | Increased responsiveness of presumed 5-HT cells to citalopram in adult rats subjected to prolonged maternal separation relative to brief separation | |
| Hutchinson et al. | Reduction of opioid withdrawal and potentiation of acute opioid analgesia by systemic AV411 (ibudilast) | |
| Daenen et al. | Adaptation and habituation to an open field and responses to various stressful events in animals with neonatal lesions in the amygdala or ventral hippocampus | |
| Knoll et al. | Kappa opioid receptor signaling in the basolateral amygdala regulates conditioned fear and anxiety in rats | |
| Million et al. | CRF2 receptor activation prevents colorectal distension induced visceral pain and spinal ERK1/2 phosphorylation in rats | |
| Joseph et al. | The angiotensin type 2 receptor agonist Compound 21 elicits cerebroprotection in endothelin-1 induced ischemic stroke | |
| JP2008512394A5 (cg-RX-API-DMAC7.html) | ||
| Beamer et al. | N w‐Propyl‐l‐arginine (L‐NPA) reduces status epilepticus and early epileptogenic events in a mouse model of epilepsy: behavioural, EEG and immunohistochemical analyses | |
| Brait et al. | Chemokine-related gene expression in the brain following ischemic stroke: no role for CXCR2 in outcome | |
| Klausner et al. | The role of corticotropin releasing factor and its antagonist, astressin, on micturition in the rat | |
| Covington III et al. | NMDA receptors in the rat VTA: a critical site for social stress to intensify cocaine taking | |
| Ebbinghaus et al. | The anti-inflammatory effects of sympathectomy in murine antigen-induced arthritis are associated with a reduction of Th1 and Th17 responses | |
| Sun et al. | Alterations of NR2B and PSD-95 expression in hippocampus of kainic acid-exposed rats with behavioural deficits | |
| LeBlanc et al. | Plasma dopamine and noradrenaline variations in response to stress | |
| Abraham et al. | β1-and β2-adrenoceptor induced synaptic facilitation in rat basolateral amygdala | |
| Matuszewich et al. | Partial antagonism of 8-OH-DPAT'S effects on male rat sexual behavior with a D2, but not a 5-HT1A, antagonist | |
| Yamaoka et al. | Different analgesic effects of adenosine between postoperative and neuropathic pain | |
| Seyer et al. | Cannula implantation into the lateral ventricle does not adversely affect recognition or spatial working memory | |
| Meade et al. | Kappa opioid receptors mediate an initial aversive component of paclitaxel-induced neuropathy | |
| Chajra et al. | Opioid receptor delta as a global modulator of skin differentiation and barrier function repair | |
| RU2008116567A (ru) | Биомаркеры | |
| McGaraughty et al. | Antagonism of TRPV1 receptors indirectly modulates activity of thermoregulatory neurons in the medial preoptic area of rats | |
| Banks et al. | Antinociceptive interactions between Mu-opioid receptor agonists and the serotonin uptake inhibitor clomipramine in rhesus monkeys: role of Mu agonist efficacy |